🇺🇸

US SEC Filing Intelligence

· daily

General Federal Contracts — August 08, 2026

This digest covers $929 million in civilian-agency contract obligations from August 8, 2026, with zero defense-related awards. ICE’s $228.5 million ISAP award to B.I. Incorporated (GEO Group) is the highest-conviction signal, reinforcing GEO’s moat in immigration detention alternatives. DHS IT support to SAIC ($96.2M, with $741.7M potential) and NIH’s PATH study award to Westat ($85.5M, with $780.5M potential) provide strong, low-risk revenue streams. However, five of eight contracts are neutral signals, reflecting high competition, aging performance periods, or private parent companies—limiting near-term market catalysts. The dominant civilian theme is immigration enforcement technology and health research IT, but budget uncertainty under a potential Continuing Resolution (CR) and ICE policy changes are key risks.

8 total filings
· daily

All NASA Contracts — August 08, 2026

This digest covers a single NASA contract awarded to Guardians of Honor, LLC valued at $86.98 million obligated out of a $233 million ceiling, representing a civilian agency education support services award with no defense-related content. The contract is a firm fixed-price (FFP) structure, offering margin upside but execution risk for this small business, and carries a neutral signal strength of 6/10 with low materiality. The sole award provides near-term revenue visibility of ~$29M annually through October 2025, but the lack of competitive moat and concentration risk in a single task order warrants monitoring. Key risk is the company's ability to manage fixed-price cost overruns given its small business status, while the opportunity lies in potential option exercises under the IDIQ vehicle.

1 total filings
· daily

Federal Construction & Infrastructure Contracts — August 07, 2026

This digest covers a single $88.2 million firm-fixed-price contract awarded to Suffolk Construction Company by the Department of Veterans Affairs for boiler replacement and control upgrades at a VA hospital in West Roxbury, MA. The award is entirely civilian (VA) and represents a competitively won infrastructure project with a three-year performance period. The highest-conviction signal is neutral, reflecting stable revenue visibility offset by fixed-price execution risk and competitive margin pressure. Key risks include potential cost overruns on a fixed-price contract and the lack of follow-on awards, while the opportunity lies in monitoring VA capital construction spending for similar infrastructure upgrades.

1 total filings
· daily

VA Healthcare & Services Contracts — August 07, 2026

The sole contract in this digest is an $88.2 million firm-fixed-price award from the Department of Veterans Affairs (VA) to Suffolk Construction Company for boiler replacement and control upgrades at a hospital in West Roxbury, MA. This is a purely civilian (VA) infrastructure project, with no defense-related content, and represents a stable but low-growth signal for the construction sector. The contract, won under full-and-open competition, provides Suffolk Construction with moderate revenue visibility over a three-year period (2026-2029), but carries execution risk due to the fixed-price nature. The highest-conviction signal is the VA's continued investment in legacy infrastructure, which may indicate a steady pipeline for construction firms but also highlights the lack of high-tech or defense-driven opportunities in this stream. Key risks include potential cost overruns on the fixed-price contract and the VA's budget sensitivity to continuing resolutions.

1 total filings
· daily

Biotech Small-Cap Approvals — August 07, 2026

The August 7, 2026 digest covers three biosimilar (FALLBACK) approvals with no NMEs, biosimilars, or label expansions, resulting in a neutral signal mix. The dominant theme is generic/biosimilar entry into established markets, with approvals for SACUBITRIL (UMEDICA), NINTEDANIB ESYLATE (MACLEODS PHARMS LTD), and INDOCYANINE GREEN (ZYDUS LIFESCIENCES). The highest-conviction signal is the SACUBITRIL biosimilar approval for UMEDICA, which introduces competition in the heart failure space, though commercial data is undisclosed. A key watch item is the lack of disclosed peak sales, exclusivity, or pricing power, limiting near-term investment conviction.

3 total filings
· daily

NME Blockbuster Approvals — August 07, 2026

This digest covers a single FDA approval event on August 7, 2026, comprising one NME approval (Oveporexton by Takeda Pharma USA) with no biosimilars or label expansions. The dominant therapeutic area is not clearly defined from this single event, but the approval of Oveporexton (ORZEYFUL) under Priority Review signals a high-unmet-need indication. The highest-conviction signal is bullish for Takeda, given the NME status and Priority Review designation, which historically correlate with strong commercial potential. A key watch item is the lack of disclosed peak sales estimates, exclusivity, and pricing power, which limits full investment assessment.

1 total filings
· daily

Big Pharma Approvals — August 07, 2026

During this single-day period, the FDA approved one NME, OVEPOREXTON (ORZEYFUL) from Takeda Pharmaceuticals USA, under Priority Review, signaling a bullish event for the sponsor. No biosimilars or label expansions were approved, making this a focused, high-signal approval. The dominant therapeutic area theme is not explicitly stated but the NME designation and Priority Review suggest a significant unmet medical need. The highest-conviction signal is Takeda's NME approval, which strengthens its pipeline credibility and commercial portfolio. Key risk is the lack of disclosed commercial data (peak sales, pricing, exclusivity), which limits full investment assessment.

1 total filings
· daily

New Drug Approvals (Original) — August 07, 2026

The August 7, 2026 FDA approval digest features 4 total approvals with zero NMEs, zero biosimilars, zero label expansions, and 4 'Other' designations, indicating a quiet period for novel therapeutic catalysts. The sole bullish signal comes from Takeda Pharmaceuticals USA's NME approval of Oveporexton (ORZEYFUL), granted Priority Review, signaling strong unmet need and potential commercial differentiation despite undisclosed peak sales estimates. The remaining three approvals are neutral biosimilar entries from Umedica (Sacubitril), Macleods Pharma (Nintedanib Esylate), and Zydus Lifesciences (Indocyanine Green), which introduce competitive pressure on originator franchises but lack disclosed pricing or market position data. Key risk: the absence of NME approvals outside Takeda's single asset limits sector-wide pipeline conviction for this period, while biosimilar approvals for Sacubitril and Nintedanib Esylate could erode originator revenues in cardiovascular and pulmonary markets respectively. Investors should monitor Takeda's launch execution for Oveporexton as the highest-conviction signal, and watch for payer coverage decisions on the biosimilars to gauge revenue erosion magnitude.

4 total filings
· daily

HHS & Healthcare Contracts Intelligence — August 07, 2026

During the period August 7, 2026, a single HHS contract worth $155.8 million was awarded to Merck Sharp & Dohme LLC for ERVEBO procurement, a civilian biodefense and pandemic preparedness action. The contract is entirely civilian (0% defense-related) and carries a moderate signal strength of 6/10 due to the firm-fixed-price structure and multi-year option uncertainty. The highest-conviction signal is Merck’s long-term revenue visibility from a 10-year base-plus-options vehicle, but investors should watch execution risk if production costs exceed the fixed price and the timing of option exercises totaling $17.8 million.

1 total filings
· daily

New Federal Contractors — August 07, 2026

This digest of 7 new federal contracts, totaling $1.26 billion, reveals a pronounced civilian agency tilt, with only 2 of 7 awards being defense-related. The dominant theme is sustained U.S. government investment in health security and biodefense, led by two substantial awards to Merck Sharp & Dohme LLC from HHS/BARDA totaling $392.1 million. The highest-conviction signal is Merck's dual contract wins, which provide long-term revenue visibility through 2034 and align with enduring pandemic preparedness priorities. A key risk is the concentration of awards to a single entity (Merck) and the absence of defense-related signals, which may limit exposure to growth in the defense budget. Investors should watch for the exercise of Merck's $72.9 million in combined contract options as a key catalyst.

7 total filings
· daily

Significant Contract Modifications ($10M+) — August 07, 2026

The 7 contracts analyzed, valued at $1.26 billion aggregate, are overwhelmingly civilian-agency awards (5 of 7), with the Department of Health and Human Services (HHS) emerging as the dominant spender via two Merck Sharp & Dohme contracts totaling $392.2 million for biodefense and pharmaceutical procurement. The highest-conviction bullish signal is Merck's dual HHS/BARDA awards, reflecting durable government biodefense funding, while the sole defense-related contract—Whitney Bradley & Brown's $108 million GSA delivery order—is neutral but exposes Serco Limited's subsidiary to firm-fixed-price execution risk. Key risks include the expiration of the ARCTIC SLOPE Technical Services $388.5 million NASA contract (fully performed, zero future upside) and concentration at HHS. Investors should monitor option exercises on Merck's BARDA contract through 2034 and Suffolk Construction's execution of a fixed-price $88.2 million VA boiler replacement project.

7 total filings
· daily

Contract Deobligations Alert — August 07, 2026

The seven contracts analyzed, totaling $1.26 billion, are overwhelmingly civilian (5 of 7), with the Department of Health and Human Services (HHS) and its BARDA agency dominating the award value via two large contracts to Merck Sharp & Dohme LLC worth $392.2 million combined. The highest-conviction signal is the dual Merck awards, which provide long-term, low-risk revenue visibility from a key biodefense agency, though the cost-plus structure on the larger award limits profit upside. A key risk is the concentration of awards to Merck, which creates single-entity dependency for the biodefense theme, and the completed nature of the largest contract (Arctic Slope Technical Services) means its revenue is non-recurring.

7 total filings
· daily

Contract Option Exercises — August 07, 2026

The seven contract awards totaling $1.26 billion present a predominantly civilian-focused opportunity set, with only two defense-related awards (28.6% of count) and a heavy concentration in health and infrastructure agencies. The most compelling signal is Merck Sharp & Dohme's two HHS/BARDA awards totaling $392.1 million for pharmaceutical R&D and ERVEBO procurement, reflecting sustained biodefense spending post-COVID. The highest-conviction single award is SENTURE LLC's $105.6 million DOT contract, fully funded and competitively won, offering predictable revenue through 2025. Key risks include the completion of Arctic Slope Technical Services' $388.5 million NASA contract (no future revenue) and fixed-price execution risk across multiple awards, particularly Suffolk Construction's $88.2 million VA boiler project. Investors should watch for option exercises on Merck's contracts and the re-compete of SENTURE's FMCSA work.

7 total filings
· daily

Federal IT & Cybersecurity Contracts — August 07, 2026

This digest covers a single $105.6 million civilian contract awarded to SENTURE LLC by the Department of Transportation's Federal Motor Carrier Safety Administration (FMCSA) for Customer Insurance and Registration Information Support (CIRIS) services. The contract is fully funded, runs through August 2025, and represents a long-term, predictable revenue stream for SENTURE. As a civilian agency award with no defense involvement, it highlights stable IT services demand outside the DoD. The highest-conviction signal is bullish, given the fully obligated funding and competitive award process, but the fixed-price structure introduces execution risk if costs overrun.

1 total filings
· daily

All HHS Contracts — August 07, 2026

Over a single-day period, HHS awarded two contracts totaling $392.2 million exclusively to Merck Sharp & Dohme LLC, with one contract classified as defense-related. The dominant theme is BARDA’s sustained investment in biodefense and pandemic preparedness, with both awards supporting pharmaceutical R&D and procurement. The highest-conviction signal is the $236.3 million cost-plus-fixed-fee contract, which provides low-risk, long-term revenue visibility through 2027. A key risk is the medium pricing risk on the $155.8 million firm-fixed-price ERVEBO contract, which could compress margins if production costs rise.

2 total filings
· daily

Mega Contracts Monitor ($100M+) — August 07, 2026

This digest covers six mega contracts totaling $1.18 billion, with a clear civilian tilt (4 of 6 contracts) and a dominant theme of health security and IT modernization. The highest-conviction signal is Merck Sharp & Dohme's two HHS/BARDA awards totaling $392.2 million, reflecting sustained government investment in biodefense and pandemic preparedness. A key risk is the completed performance of the largest contract (Arctic Slope Technical Services, $388.5 million), which provides no future revenue. Investors should watch for option exercises on Merck's contracts and the re-compete of SENTURE's DOT award as near-term catalysts.

6 total filings
· daily

High-Value Federal Grants ($5M+) — August 07, 2026

This digest covers $1.26 billion in high-value federal grants and contracts, with a pronounced civilian tilt (5 of 7 awards) and a dominant theme of biodefense and pharmaceutical procurement via BARDA/HHS. The highest-conviction signal is Merck Sharp & Dohme's combined $392 million in two separate BARDA awards (one cost-plus, one firm-fixed-price for ERVEBO), reflecting sustained government commitment to pandemic preparedness and biodefense through 2034. A key risk is the concentration of awards to a single pharmaceutical entity (Merck) and the unknown competition status on the ERVEBO sole-source contract, which limits visibility into pricing power and margin durability. Defense-related contracts (2 of 7) are lower materiality and largely completed, offering limited forward-looking signals for the defense sector.

7 total filings
· daily

General Federal Contracts — August 07, 2026

This digest covers $1.26 billion in federal obligations across 7 contracts, with a pronounced civilian tilt (5 of 7 awards, 71% of total value) versus defense (2 awards, 16% of total). The dominant sector theme is health security and biodefense, driven by two Merck Sharp & Dohme contracts from HHS/BARDA totaling $392.1 million, signaling sustained government investment in pandemic preparedness and medical countermeasures post-COVID-19. The highest-conviction signal is Merck's dual BARDA wins, which provide long-term (10-year) revenue visibility with low pricing risk. A key risk is the concentration of obligations in completed or expiring contracts—$388.5 million from Arctic Slope Technical Services (NASA) and $108 million from Whitney Bradley & Brown (GSA) have already concluded performance periods, limiting future revenue contribution.

7 total filings
· daily

All NASA Contracts — August 07, 2026

This digest covers a single NASA contract totaling $388.5 million awarded to Arctic Slope Technical Services, Inc., an Alaskan Native Corporation-owned 8(a) firm. The contract is purely civilian (0% defense-related) and was executed under a cost-plus-fixed-fee structure from 2015 to 2022, providing low-risk, stable revenue during its performance period. The highest-conviction signal is the competitive moat provided by the 8(a) set-aside, though the contract's completion means no future revenue from this award. A key risk is the lack of follow-on contracts, which could indicate a gap in Arctic Slope's revenue pipeline.

1 total filings
· daily

S&P 500 Technology Sector SEC Filings — August 07, 2026

The 19 filings from the S&P 500 Technology sector reveal a heavy insider selling pattern across key names (Arista, Lam Research, Datadog), with most sales executed under Rule 10b5-1 plans, reducing alarm but signaling potential price ceiling concerns. KLA Corp's executive team collectively received large equity awards but also had significant shares withheld for taxes, a routine but large cash-out event. State Street Corporation filed passive 5%+ stakes in Adobe, Cisco, and Qualcomm, indicating broad institutional accumulation in mega-cap tech. No revenue, margin, or guidance data exists in these insider and beneficial ownership filings, so sector trends rely entirely on insider behavior. The dominant insider selling at Arista Networks ($102.7M total) from both CEO and 10% owner is the standout signal, especially given the company's recent performance and high valuation. The Lam Research CEO's $9M sale at $300, coupled with Lam's 10-K risk filing (medium risk/8 materiality), flags possible headwinds. Overall, the batch suggests a cautious tone among C-suite executives at high-growth names, with no bullish insider buying detected.

15 high priority 4 medium 19 total filings